NoteRemarkable increase of Neisseria gonorrhoeae with decreased susceptibility of azithromycin and increase in the failure of azithromycin therapy in male gonococcal urethritis in Sendai in 2015
Section snippets
Conflict of interest
This work was supported in part by the Japan Society for the Promotion of Science (JSPS), Japan (Grant-in-Aid for Scientific Research [C] 25462509 and [C] 26462442) and by the Research Program on Emerging and Re-emerging Infectious Diseases, Japan Agency for Medical Research and Development (15fk0108014h0001).
Acknowledgements
We thank the patients of iClinic, Sendai, Japan.
References (15)
- et al.
The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012–2013
J Infect Chemother
(2015) - et al.
Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype
Int J Antimicrob Agents
(2006) - et al.
Japanese guideline for clinical research of antimicrobial agents on urogenital infections: the first edition
J Infect Chemother
(2011) - et al.
Remarkable increase in central Japan in 2001–2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones
Antimicrob Agents Chemother
(2004) - et al.
Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan
Antimicrob Agents Chemother
(2005) - et al.
Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae
Int J Urol
(2008) - et al.
Microbiological efficacy and tolerability of a single-dose regimen of ceftriaxone 1 g in men with gonococcal urethritis
J Antimicrob Chemother
(2016)
Cited by (21)
The JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders
2021, Journal of Infection and ChemotherapyCitation Excerpt :While the spread of CTRX-resistant strains has not been observed, increases in CTRX low-sensitivity strains have been reported from various parts of the world [57,83], and their trends are attracting attention (IV, B). Although AZM is recognized to be effective against gonococcal infection, there have been a number of reports of regional surveillance data indicating decreases in responses to this drug [84]. Moreover, as there have been a series of reports of N. gonorrhoeae strains highly resistant to AZM from foreign countries, AZM is not recommended as the first-line drug in the Japanese guidelines [67–71] (II, B).
Urethritis
2020, FMC Formacion Medica Continuada en Atencion PrimariaManagement of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments?
2019, European Urology FocusCitation Excerpt :Owing to the widespread high levels of cephalosporin resistance, first-line treatment consists of combined therapy using a single dose of ceftriaxone 250 mg (1 g IM) plus azithromycin 1 g (2 g orally), although the European Association of Urology guideline recommendation indicated the need to administer at least ceftriaxone 1 g in combination with azithromycin 1 g to avoid the risk of undertreatment (LE 2a) [2,14,21,26,27]. Azithromycin is preferred to doxycycline because of the convenience and compliance advantages of single-dose therapy and the substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin (LE 2a) [28,29]. Therefore, this dual therapy will not entirely prevent the emerging resistance.
Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study
2018, The Lancet Infectious DiseasesCitation Excerpt :Even low-level azithromycin resistance is likely to render the azithromycin component of dual therapy ineffective. In a Japanese study,27 treatment failures in men with gonococcal urethritis treated with an extended-release 2 g azithromycin single dose were associated with azithromycin MICs of higher than 0·5 mg/L. Additionally, the in-vitro MIC of azithromycin does not necessarily correlate with clinical treatment outcome, and treatment failures occur in patients with isolates identified as azithromycin susceptible in the laboratory.28 In conclusion, sustained transmission of a successful HL-AziR N gonorrhoeae clone has been observed across England.
Health risks and precautions for visitors to the Tokyo 2020 Olympic and Paralympic Games
2018, Travel Medicine and Infectious DiseaseCitation Excerpt :Among the cases in 2016, 37% (1673 cases) were reported from Tokyo [52]. In addition, there are increasing numbers of drug-resistant gonorrhea cases globally, including in Japan [53–55]. The total number of non-drug resistant gonorrhea cases in Japan was 8298 in 2016, decreasing from 8698 in 2015 [51]; however, this disease could spread both within and outside Japan, which may result in epidemics across different countries.